Abstract
As one of the most studied ribonucleic acid (RNA) modifications in eukaryotes, N(6) -methyladenosine (m(6) A) has been shown to play a predominant role in controlling gene expression and influence physiological and pathological processes such as oncogenesis and tumor progression. Writer and eraser proteins, acting opposite to deposit and remove m(6) A epigenetic marks, respectively, shape the cellular m(6) A landscape, while reader proteins preferentially recognize m(6) A modifications and mediate fate decision of the methylated RNAs, including RNA synthesis, splicing, exportation, translation, and stability. Therefore, RNA metabolism in cells is greatly influenced by these three classes of m(6) A regulators. Aberrant expression of m(6) A regulators has been widely reported in various types of cancer, leading to cancer initiation, progression, and drug resistance. The close links between m(6) A and cancer shed light on the potential use of m(6) A methylation and its regulators as prognostic biomarkers and drug targets for cancer therapy. Given the notable effects of m(6) A in reversing chemoresistance and enhancing immune therapy, it is a promising target for combined therapy. Herein, we summarize the recent discoveries on m(6) A and its regulators, emphasizing their influences on RNA metabolism, their dysregulation and impacts in diverse malignancies, and discuss the clinical implications of m(6) A modification in cancer.